Dr. Fraker earned his medical degree and completed his residency at The Ohio State University College of Medicine. Dr. Fraker also completed a postdoctoral fellowship in cardiovascular diseases at Duke University in Durham, N.C.
Dr. Fraker was named one of America’s Best Doctors in 2009. He is widely published in peer-reviewed journals and co-authored the 2009 ACC/AHA Guideline Update for Chronic Stable Angina. Dr. Fraker is a member of multiple professional societies, including the American Heart Association and the American College of Cardiology. He is also a past president of the Ohio chapter of the American College of Cardiology.
Dr. Fraker’s specialty interests include nuclear cardiology, echocardiography and clinical cardiology, and his research focuses on evidence-based medicine, clinical practice efficiency and healthcare economics.
- Rated in the top 10 percent of physicians in the nation for patient satisfaction, 2014, 2015, 2016
Ohio State University College of Medicine
Ohio State University Wexner Medical Ctr
7/1/1974 - 6/1/1976
Specialties and conditions I treat
- Cardiovascular Disease
- Internal Medicine
- Cardiovascular Diseases
- Nuclear Medicine
- Coronary Care Units
Locations where I practice
More about my work
Duke University Medical Center
7/1/1976 - 6/30/1979
American Board of Internal Medicine
American Board of Internal Medicine (Subspecialty: Cardiovascular)
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/28/17, Dr. Fraker has reported no financial relationships with medical device, research and/or drug companies.